Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 65

1.

Bowel preparation prior to minimally invasive sacrocolpopexy: a randomized controlled trial.

Sassani JC, Kantartzis K, Wu L, Fabio A, Zyczynski HM.

Int Urogynecol J. 2019 Nov 26. doi: 10.1007/s00192-019-04120-7. [Epub ahead of print]

PMID:
31773199
2.

Empagliflozin Effectively Lowers Liver Fat Content in Well-Controlled Type 2 Diabetes: A Randomized, Double-Blind, Phase 4, Placebo-Controlled Trial.

Kahl S, Gancheva S, Straßburger K, Herder C, Machann J, Katsuyama H, Kabisch S, Henkel E, Kopf S, Lagerpusch M, Kantartzis K, Kupriyanova Y, Markgraf D, van Gemert T, Knebel B, Wolkersdorfer MF, Kuss O, Hwang JH, Bornstein SR, Kasperk C, Stefan N, Pfeiffer A, Birkenfeld AL, Roden M.

Diabetes Care. 2019 Sep 20. pii: dc190641. doi: 10.2337/dc19-0641. [Epub ahead of print]

PMID:
31540903
3.

Cross-linguistically shared and language-specific sound symbolism in novel words elicited by locomotion videos in Japanese and English.

Saji N, Akita K, Kantartzis K, Kita S, Imai M.

PLoS One. 2019 Jul 10;14(7):e0218707. doi: 10.1371/journal.pone.0218707. eCollection 2019.

4.

Diabetes and heart failure: Is it hyperglycemia or hyperinsulinemia?

Didangelos T, Kantartzis K.

Curr Vasc Pharmacol. 2019 Apr 8. doi: 10.2174/1570161117666190408164326. [Epub ahead of print]

PMID:
30963973
5.

Dietary Niacin Intake Predicts the Decrease of Liver Fat Content During a Lifestyle Intervention.

Linder K, Willmann C, Kantartzis K, Machann J, Schick F, Graf M, Kümmerle S, Häring HU, Fritsche A, Stefan N, Wagner R.

Sci Rep. 2019 Feb 4;9(1):1303. doi: 10.1038/s41598-018-38002-7.

6.

Single Nucleotide Polymorphisms in the G-Protein Coupled Receptor Kinase 5 (GRK5) Gene are associated with Plasma LDL-Cholesterol Levels in Humans.

Lutz SZ, Falcenberg M, Machicao F, Peter A, Kächele M, Randrianarisoa E, Lehn-Stefan A, Wagner R, Machann J, Schick F, Heni M, Ullrich A, Fritsche A, Stefan N, Häring HU, Staiger H, Kantartzis K.

Sci Rep. 2018 May 17;8(1):7745. doi: 10.1038/s41598-018-26055-7.

7.
8.

Effects of resveratrol supplementation on liver fat content in overweight and insulin-resistant subjects: A randomized, double-blind, placebo-controlled clinical trial.

Kantartzis K, Fritsche L, Bombrich M, Machann J, Schick F, Staiger H, Kunz I, Schoop R, Lehn-Stefan A, Heni M, Peter A, Fritsche A, Häring HU, Stefan N.

Diabetes Obes Metab. 2018 Jul;20(7):1793-1797. doi: 10.1111/dom.13268. Epub 2018 Mar 22.

PMID:
29484808
9.

Androgen receptor overexpression in prostate cancer in type 2 diabetes.

Lutz SZ, Hennenlotter J, Scharpf MO, Sailer C, Fritsche L, Schmid V, Kantartzis K, Wagner R, Lehmann R, Berti L, Peter A, Staiger H, Fritsche A, Fend F, Todenhöfer T, Stenzl A, Häring HU, Heni M.

Mol Metab. 2018 Feb;8:158-166. doi: 10.1016/j.molmet.2017.11.013. Epub 2017 Dec 5.

10.

Non-alcoholic fatty liver disease and impaired proinsulin conversion as newly identified predictors of the long-term non-response to a lifestyle intervention for diabetes prevention: results from the TULIP study.

Schmid V, Wagner R, Sailer C, Fritsche L, Kantartzis K, Peter A, Heni M, Häring HU, Stefan N, Fritsche A.

Diabetologia. 2017 Dec;60(12):2341-2351. doi: 10.1007/s00125-017-4407-z. Epub 2017 Aug 24.

PMID:
28840257
11.

The Impact of Individual Surgeon Volume on Hysterectomy Costs.

Shepherd JP, Carter-Brooks CM, Kantartzis KL, Lee T, Bonidie MJ.

JSLS. 2017 Jan-Mar;21(1). pii: e2016.00112. doi: 10.4293/JSLS.2016.00112.

12.

An extended fatty liver index to predict non-alcoholic fatty liver disease.

Kantartzis K, Rettig I, Staiger H, Machann J, Schick F, Scheja L, Gastaldelli A, Bugianesi E, Peter A, Schulze MB, Fritsche A, Häring HU, Stefan N.

Diabetes Metab. 2017 Jun;43(3):229-239. doi: 10.1016/j.diabet.2016.11.006. Epub 2017 Jan 12.

13.

Genetic Variation in the 11β-hydroxysteroid-dehydrogenase 1 Gene Determines NAFLD and Visceral Obesity.

Lutz SZ, Peter A, Machicao F, Lamprinou A, Machann J, Schick F, Königsrainer I, Königsrainer A, Fritsche A, Staiger H, Häring HU, Stefan N, Kantartzis K.

J Clin Endocrinol Metab. 2016 Dec;101(12):4743-4751. Epub 2016 Oct 7.

PMID:
27715400
14.

The use of mechanical bowel preparation in laparoscopic gynecologic surgery: a decision analysis.

Kantartzis KL, Shepherd JP.

Am J Obstet Gynecol. 2015 Nov;213(5):721.e1-5. doi: 10.1016/j.ajog.2015.05.017. Epub 2015 May 14.

PMID:
25981848
15.

Sound symbolism facilitates word learning in 14-month-olds.

Imai M, Miyazaki M, Yeung HH, Hidaka S, Kantartzis K, Okada H, Kita S.

PLoS One. 2015 Feb 19;10(2):e0116494. doi: 10.1371/journal.pone.0116494. eCollection 2015.

16.

Cost analysis when open surgeons perform minimally invasive hysterectomy.

Shepherd JP, Kantartzis KL, Ahn KH, Bonidie MJ, Lee T.

JSLS. 2014 Oct-Dec;18(4). pii: e2014.00181. doi: 10.4293/JSLS.2014.00181. Erratum in: JSLS. 2015 Jan-Mar;19(1):e2015.00027.

17.

Adoption of robotic sacrocolpopexy at an academic institution.

Bradley MS, Kantartzis KL, Lowder JL, Winger D, Wang L, Shepherd JP.

JSLS. 2014 Jul-Sep;18(3). pii: e2014.00237. doi: 10.4293/JSLS.2014.00237.

18.

Predictors of postoperative acute urinary retention in women undergoing minimally invasive sacral colpopexy.

Turner LC, Kantartzis K, Shepherd JP.

Female Pelvic Med Reconstr Surg. 2015 Jan-Feb;21(1):39-42. doi: 10.1097/SPV.0000000000000110.

PMID:
25185611
19.

Apical support at the time of hysterectomy for uterovaginal prolapse.

Kantartzis KL, Turner LC, Shepherd JP, Wang L, Winger DG, Lowder JL.

Int Urogynecol J. 2015 Feb;26(2):207-12. doi: 10.1007/s00192-014-2474-y. Epub 2014 Sep 3.

PMID:
25182150
20.

The effect of age on complications in women undergoing minimally invasive sacral colpopexy.

Turner LC, Kantartzis K, Lowder JL, Shepherd JP.

Int Urogynecol J. 2014 Sep;25(9):1251-6. doi: 10.1007/s00192-014-2391-0. Epub 2014 May 6.

PMID:
24797942
21.

Inhibition of 11β-HSD1 with RO5093151 for non-alcoholic fatty liver disease: a multicentre, randomised, double-blind, placebo-controlled trial.

Stefan N, Ramsauer M, Jordan P, Nowotny B, Kantartzis K, Machann J, Hwang JH, Nowotny P, Kahl S, Harreiter J, Hornemann S, Sanyal AJ, Stewart PM, Pfeiffer AF, Kautzky-Willer A, Roden M, Häring HU, Fürst-Recktenwald S.

Lancet Diabetes Endocrinol. 2014 May;2(5):406-16. doi: 10.1016/S2213-8587(13)70170-0. Epub 2014 Feb 17.

PMID:
24795254
22.

Cost-effectiveness of test phase implantation strategies for InterStim® sacral neuromodulation.

Kantartzis KL, Shepherd JP.

Female Pelvic Med Reconstr Surg. 2013 Nov-Dec;19(6):322-7. doi: 10.1097/SPV.0b013e3182a5deb4.

PMID:
24165444
23.

Introduction of laparoscopic sacral colpopexy to a fellowship training program.

Kantartzis K, Sutkin G, Winger D, Wang L, Shepherd J.

Int Urogynecol J. 2013 Nov;24(11):1877-81. doi: 10.1007/s00192-013-2085-z. Epub 2013 Apr 3.

24.

Circulating lysophosphatidylcholines are markers of a metabolically benign nonalcoholic fatty liver.

Lehmann R, Franken H, Dammeier S, Rosenbaum L, Kantartzis K, Peter A, Zell A, Adam P, Li J, Xu G, Königsrainer A, Machann J, Schick F, Hrabé de Angelis M, Schwab M, Staiger H, Schleicher E, Gastaldelli A, Fritsche A, Häring HU, Stefan N.

Diabetes Care. 2013 Aug;36(8):2331-8. doi: 10.2337/dc12-1760. Epub 2013 Mar 20.

25.

Menstrual suppression in the adolescent.

Kantartzis KL, Sucato GS.

J Pediatr Adolesc Gynecol. 2013 Jun;26(3):132-7. doi: 10.1016/j.jpag.2012.08.007. Epub 2012 Nov 15. Review.

PMID:
23158755
26.

Sacral neuromodulation and intravesical botulinum toxin for refractory overactive bladder.

Kantartzis K, Shepherd J.

Curr Opin Obstet Gynecol. 2012 Oct;24(5):331-6. doi: 10.1097/GCO.0b013e3283573ff9. Review.

PMID:
22922403
27.

Insulin resistant phenotype of polycystic ovary syndrome does not seem to be caused by variation in FTO.

Hatziagelaki E, Wagner R, Kantartzis K, Heni M, Linder K, Ketterer C, Machicao F, Stefan N, Staiger H, Häring HU, Fritsche A.

Horm Metab Res. 2012 Oct;44(11):810-3. doi: 10.1055/s-0032-1321817. Epub 2012 Jul 30.

PMID:
22847851
28.

Cardiovascular disease in patients with non-alcoholic fatty liver disease.

Kantartzis K, Stefan N.

Ann Gastroenterol. 2012;25(3):276-277. No abstract available.

29.

Cholesterol synthesis is associated with hepatic lipid content and dependent on fructose/glucose intake in healthy humans.

Silbernagel G, Lütjohann D, Machann J, Meichsner S, Kantartzis K, Schick F, Häring HU, Stefan N, Fritsche A.

Exp Diabetes Res. 2012;2012:361863. doi: 10.1155/2012/361863. Epub 2011 Nov 29.

30.

Diabetes and nonalcoholic fatty liver disease.

Kantartzis K, Gastaldelli A, Magkos F, Lavoie JM.

Exp Diabetes Res. 2012;2012:404632. doi: 10.1155/2012/404632. Epub 2011 Dec 14. No abstract available.

31.

Diet and exercise in the treatment of Fatty liver.

Magkos F, Lavoie JM, Kantartzis K, Gastaldelli A.

J Nutr Metab. 2012;2012:257671. doi: 10.1155/2012/257671. Epub 2011 Sep 18. No abstract available.

32.

New type 2 diabetes risk genes provide new insights in insulin secretion mechanisms.

Schäfer SA, Machicao F, Fritsche A, Häring HU, Kantartzis K.

Diabetes Res Clin Pract. 2011 Aug;93 Suppl 1:S9-24. doi: 10.1016/S0168-8227(11)70008-0. Review.

PMID:
21864758
33.

Visceral obesity modulates the impact of apolipoprotein C3 gene variants on liver fat content.

Peter A, Kantartzis K, Machicao F, Machann J, Wagner S, Templin S, Königsrainer I, Königsrainer A, Schick F, Fritsche A, Häring HU, Stefan N.

Int J Obes (Lond). 2012 Jun;36(6):774-82. doi: 10.1038/ijo.2011.154. Epub 2011 Aug 9.

PMID:
21829161
34.

Global trends in body-mass index.

Stefan N, Kantartzis K, Machann J, Schick F, Häring HU.

Lancet. 2011 Jun 4;377(9781):1917; author reply 1917-8. doi: 10.1016/S0140-6736(11)60805-2. No abstract available.

PMID:
21641474
35.

Cardiorespiratory fitness determines the reduction in blood pressure and insulin resistance during lifestyle intervention.

Totsikas C, Röhm J, Kantartzis K, Thamer C, Rittig K, Machann J, Schick F, Hansel J, Niess A, Fritsche A, Häring HU, Stefan N.

J Hypertens. 2011 Jun;29(6):1220-7. doi: 10.1097/HJH.0b013e3283469910.

PMID:
21505353
36.

Type 2 diabetes mellitus and risk of malignancy: is there a strategy to identify a subphenotype of patients with increased susceptibility to endogenous and exogenous hyperinsulinism?

Müssig K, Staiger H, Kantartzis K, Fritsche A, Kanz L, Häring HU.

Diabet Med. 2011 Mar;28(3):276-86. doi: 10.1111/j.1464-5491.2010.03132.x. Review.

PMID:
21309835
37.

Effects of a lifestyle intervention in metabolically benign and malign obesity.

Kantartzis K, Machann J, Schick F, Rittig K, Machicao F, Fritsche A, Häring HU, Stefan N.

Diabetologia. 2011 Apr;54(4):864-8. doi: 10.1007/s00125-010-2006-3. Epub 2010 Dec 21.

PMID:
21174075
38.

Evaluation of fasting state-/oral glucose tolerance test-derived measures of insulin release for the detection of genetically impaired β-cell function.

Herzberg-Schäfer SA, Staiger H, Heni M, Ketterer C, Guthoff M, Kantartzis K, Machicao F, Stefan N, Häring HU, Fritsche A.

PLoS One. 2010 Dec 2;5(12):e14194. doi: 10.1371/journal.pone.0014194.

39.

Relationships of circulating sex hormone-binding globulin with metabolic traits in humans.

Peter A, Kantartzis K, Machann J, Schick F, Staiger H, Machicao F, Schleicher E, Fritsche A, Häring HU, Stefan N.

Diabetes. 2010 Dec;59(12):3167-73. doi: 10.2337/db10-0179. Epub 2010 Sep 14.

40.

Follow-up whole-body assessment of adipose tissue compartments during a lifestyle intervention in a large cohort at increased risk for type 2 diabetes.

Machann J, Thamer C, Stefan N, Schwenzer NF, Kantartzis K, Häring HU, Claussen CD, Fritsche A, Schick F.

Radiology. 2010 Nov;257(2):353-63. doi: 10.1148/radiol.10092284. Epub 2010 Aug 16.

PMID:
20713612
41.

Environmental and genetic determinants of fatty liver in humans.

Kantartzis K, Schick F, Häring HU, Stefan N.

Dig Dis. 2010;28(1):169-78. doi: 10.1159/000282082. Epub 2010 May 7. Review.

PMID:
20460907
42.

[Diabetes, insulin, insulin analogues, and cancer].

Müssig K, Staiger H, Kantartzis K, Fritsche A, Kanz L, Häring HU.

Dtsch Med Wochenschr. 2010 May;135(18):924-9. doi: 10.1055/s-0030-1253681. Epub 2010 Apr 27. Review. German.

PMID:
20425680
43.

The impact of liver fat vs visceral fat in determining categories of prediabetes.

Kantartzis K, Machann J, Schick F, Fritsche A, Häring HU, Stefan N.

Diabetologia. 2010 May;53(5):882-9. doi: 10.1007/s00125-010-1663-6. Epub 2010 Jan 23.

PMID:
20099057
44.

The ENPP1 K121Q polymorphism determines individual susceptibility to the insulin-sensitising effect of lifestyle intervention.

Müssig K, Heni M, Thamer C, Kantartzis K, Machicao F, Stefan N, Fritsche A, Häring HU, Staiger H.

Diabetologia. 2010 Mar;53(3):504-9. doi: 10.1007/s00125-009-1612-4. Epub 2009 Nov 29.

PMID:
20091022
45.

Circulating palmitoleate strongly and independently predicts insulin sensitivity in humans.

Stefan N, Kantartzis K, Celebi N, Staiger H, Machann J, Schick F, Cegan A, Elcnerova M, Schleicher E, Fritsche A, Häring HU.

Diabetes Care. 2010 Feb;33(2):405-7. doi: 10.2337/dc09-0544. Epub 2009 Nov 4.

46.

Dissociation between fatty liver and insulin resistance in humans carrying a variant of the patatin-like phospholipase 3 gene.

Kantartzis K, Peter A, Machicao F, Machann J, Wagner S, Königsrainer I, Königsrainer A, Schick F, Fritsche A, Häring HU, Stefan N.

Diabetes. 2009 Nov;58(11):2616-23. doi: 10.2337/db09-0279. Epub 2009 Aug 3.

47.

Association of type 2 diabetes candidate polymorphisms in KCNQ1 with incretin and insulin secretion.

Müssig K, Staiger H, Machicao F, Kirchhoff K, Guthoff M, Schäfer SA, Kantartzis K, Silbernagel G, Stefan N, Holst JJ, Gallwitz B, Häring HU, Fritsche A.

Diabetes. 2009 Jul;58(7):1715-20. doi: 10.2337/db08-1589. Epub 2009 Apr 14.

48.

Adiponectin oligomers and ectopic fat in liver and skeletal muscle in humans.

Kantartzis K, Staiger H, Machann J, Schick F, Claussen CD, Machicao F, Fritsche A, Häring HU, Stefan N.

Obesity (Silver Spring). 2009 Feb;17(2):390-2. doi: 10.1038/oby.2008.487. Epub 2008 Oct 30.

49.

Polymorphisms within the novel type 2 diabetes risk locus MTNR1B determine beta-cell function.

Staiger H, Machicao F, Schäfer SA, Kirchhoff K, Kantartzis K, Guthoff M, Silbernagel G, Stefan N, Häring HU, Fritsche A.

PLoS One. 2008;3(12):e3962. doi: 10.1371/journal.pone.0003962. Epub 2008 Dec 17.

50.

High cardiorespiratory fitness is an independent predictor of the reduction in liver fat during a lifestyle intervention in non-alcoholic fatty liver disease.

Kantartzis K, Thamer C, Peter A, Machann J, Schick F, Schraml C, Königsrainer A, Königsrainer I, Kröber S, Niess A, Fritsche A, Häring HU, Stefan N.

Gut. 2009 Sep;58(9):1281-8. doi: 10.1136/gut.2008.151977. Epub 2008 Dec 11.

PMID:
19074179

Supplemental Content

Loading ...
Support Center